NYSE: MOH · Healthcare Plans
Molina Healthcare (MOH) fair value: undervalued or overvalued?
As of 17 Nov 2026, Faircurve's model values Molina Healthcare (MOH) at $227.64 a share. The stock last closed at $221.21, which puts the model's fair value 2.9% above the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 17 Nov 2026. Molina Healthcare, Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 17 Nov 2026 moved the fair value from $208.40 to $227.64 (+9.2%).
What the model makes of itThe price of $221.21 is 2.9% below it: Fairly valued, on a medium evidence grade.
What's nextNext report on 4 Feb 2027. Options prices imply a move of about 14% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give MOH?
The calibrated range for MOH over 63 trading days is $188.36 to $261.91. It sits around the last close, and its width comes from the volatility that MOH's own options imply (49% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $183.62 to $281.15. In 46% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 17 Nov 2026
Molina Healthcare, Inc. (MOH) offers comprehensive managed health care services, primarily targeting economically disadvantaged families and individuals.
Faircurve's model put the fair value at $227.64 a share on 17 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 14 Nov 2026, gave $208.40, so the fair value moved +9.2%. The calibrated range over 63 trading days is $198.47 to $275.98, built around the price from the volatility the stock's own options imply. Ranges built this way held the price 60% of the time at this horizon, based on 8,038 past valuations. The evidence grade is Medium, which looks at input completeness, the number and agreement of comparable companies, and the spread of outcomes. It does not say whether the fair value is right.
Molina Healthcare scores 53 out of 100 on the model's overall quality measure, a composite of six factors scored against comparable companies. Balance sheet scores 70, with net debt to EBITDA of -1.59x against a peer median of 2.40x. Stability scores 69, with five-year EBITDA margin downside volatility of 0.8 pts against a peer median of 1.0 pts. Profitability scores 36, with ROIC of 4.7% against a peer median of 10.1%. The model compares the company with Centene, Progyny, Humana, Cigna, Elevance Health, CVS Health and UnitedHealth Group.
Written from the figures on this page for the 17 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does MOH report earnings, and how has the stock reacted?
Molina Healthcare's next earnings report is scheduled for 4 Feb 2027. Companies can move their dates.
Options prices on 17 Nov 2026 imply a move of about 11.1% in either direction through the nearest expiry, about 30 days out. That is the size the market is pricing, not a direction. MOH's 30 day implied volatility works out to about 14.1% over one month.
On 16 Nov 2026 MOH moved 11.3% in one session, against the 3.1% a day that options had priced: 3.7 times the implied size.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across MOH's last 8 reports, ignoring direction, was 13.2%.
What the options market has priced for a month's move in MOH
How does MOH score on business quality?
Molina Healthcare's overall quality score is 53 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 36 | 4.7%ROIC | 10.1% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 67 | ||
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 47 | 11.7%Revenue growth, trailing | 11.8% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 56 | 0.1%Net buybacks / market value | 1.5% |
| Balance sheetNet debt to EBITDA and interest coverage. | 70 | -1.59xNet debt / EBITDA | 2.40x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 69 | 0.8 ptsEBITDA margin downside volatility, 5y | 1.0 pts |
How does MOH compare with similar companies?
The companies in healthcare plans closest to Molina Healthcare in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| CNC Centene Corp. | $72.55 | $86.49 | +19.2% | Undervalued |
| PGNY Progyny, Inc. | $36.71 | $34.78 | -5.3% | Fairly valued |
| HUM Humana Inc. | $443.34 | $411.63 | -7.2% | Fairly valued |
| CI Cigna Corporation | $294.06 | $384.76 | +30.8% | Undervalued |
| ELV Elevance Health Inc. | $433.93 | $454.75 | +4.8% | Fairly valued |
| CVS CVS Health Corp. | $85.81 | $89.93 | +4.8% | Fairly valued |
| UNH UnitedHealth Group Incorporated | $389.68 | $405.70 | +4.1% | Fairly valued |
What the comparable companies' multiples alone would give for MOH, the peer-implied price, is $208.92 a share on this run. The fair value weighs that against the company's own multiple.
Molina Healthcare at a glance
Molina Healthcare, Inc. offers comprehensive managed health care services, primarily targeting economically disadvantaged families and individuals.
- Market value
- $10.9B
- Sector
- Healthcare
- Industry
- Healthcare Plans
- Revenue expected, next twelve months
- $47.3B
- Consensus revenue growth, next fiscal year
- -1.5%
- Analysts with estimates
- 11
- Beta to the US market
- -0.01
- First valued by Faircurve
- 11 Jul 2026
At the close of 17 Nov 2026, 62.4% of the 1,083 graded US stocks the model covers traded below the model's fair value. MOH was among them.
How the fair value is worked out: the model prices Molina Healthcare on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 14 Nov 2026 the model's fair value for MOH was $208.40. As of 17 Nov 2026 it is $227.64, a change of +9.2%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Molina Healthcare's valuation
Is Molina Healthcare stock undervalued or overvalued?
On Faircurve's model, MOH reads as Fairly valued as of 17 Nov 2026. The model's fair value is $227.64 a share against a last close of $221.21, a gap of +2.9%.
What is MOH's fair value?
$227.64 a share as of 17 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $183.62 to $281.15.
What price range does the model give MOH?
$188.36 to $261.91 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Molina Healthcare report earnings next?
The next report is scheduled for 4 Feb 2027. Companies can move their dates.
How much has MOH moved on past earnings reports?
Across its last 8 reports the median two session move was 13.2%, ignoring direction. The largest was -26.0% around the report of 5 Feb 2026.
How confident is the model in this valuation?
The model's evidence grade for MOH is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on MOH
The model holds no idea open on MOH today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on MOH with their outcomes. A free account is enough.